Genmab — September 2020
-
It’s not necessarily that Trillium plans to compete with a single agent; CSO Bob Uger listed anti-PD-(L)1 drugs, proteasome inhibitors, Darzalex, Erbitux and Folotyn as potential pairings for different indications. But having solid monotherapy data as a foundation gives execs more confidence that their drug would do even better in combo.
-
Genmab to present at Morgan Stanley event 15.9.20. Webcast will be available https://ir.genmab.com/news-releases/news-release-details/genmab-present-morgan-stanley-18th-annual-global-healthcare
-
New: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL https://clinicaltrials.gov/ct2/show/NCT04542824?term=NCT04542824&draw=2&rank=1
-
Join Genmab at #SOHO2020, a virtual event from September 9 to 12, 2020. Visit our virtual booth at http://genmab-at-soho-2020.com to get the latest information about our presentations, antibody platforms and pipeline. Get more info at http://soho2020.com @SocietyofHemOnc
-
If anyone is interested in a position as postdoctoral dara researcher with dr. Niels van Donk
-
https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86671_Oct_8_target.JPG mulig kursudvikling kommende måned såfremt markedet opføre sig pænt
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind